Recommendations for the definition of clinical responder in insulin preservation studies - Wikidata - wikimedia - TriplyDB

Recommendations for the definition of clinical responder in insulin preservation studies

Recommendations for the definition of clinical responder in insulin preservation studies

http://www.wikidata.org/entity/Q34077400

about

Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.Strategies for clinical trials in type 1 diabetes Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis.Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.

P2860

Q30743822-5956C996-5195-4FE5-9CC2-874BE0A69620 Q36995370-0858497F-E20B-49D0-A329-319F2CD3F494 Q38912672-5EF26FE6-7DE7-4125-83FA-DFF850DB15F3 Q40088521-8C615C98-81AE-4A68-BB24-38C3AC9FB3C8

P2860

Recommendations for the definition of clinical responder in insulin preservation studies

http://www.wikidata.org/entity/Q34077400

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Recommendations for the definition of clinical responder in insulin preservation studies

@ast

Recommendations for the definition of clinical responder in insulin preservation studies

@en

Recommendations for the definition of clinical responder in insulin preservation studies

@nl

type

label

Recommendations for the definition of clinical responder in insulin preservation studies

@ast

Recommendations for the definition of clinical responder in insulin preservation studies

@en

Recommendations for the definition of clinical responder in insulin preservation studies

@nl

prefLabel

Recommendations for the definition of clinical responder in insulin preservation studies

@ast

Recommendations for the definition of clinical responder in insulin preservation studies

@en

Recommendations for the definition of clinical responder in insulin preservation studies

@nl

P1433

Q34077400-1F6E892A-C9B1-4C73-9F29-4F2B653F5463

P1476

Q34077400-264FEE91-39D0-4708-B5C4-1DF20FDB0295

P2093

Q34077400-73F9A402-9A72-4698-8553-8F8434A41389

Q34077400-A533B24B-E6D4-40CB-A1A6-C1706ACF9E06

Q34077400-A58C324C-B3CB-415C-A73F-9C8C844D1EFE

Q34077400-E9EA804A-E79F-4684-97D6-A2A445427D6B

P2860

Q34077400-01FD8730-39E7-40A7-8DD2-BF8A169940A0

Q34077400-097F74BA-C566-4C48-8AF9-F2D0939A7F36

Q34077400-1F7B458F-CCEF-4554-995B-67397B8D9251

Q34077400-33866093-AE0A-4D68-81D2-1E0A5CAB3F2A

Q34077400-4DC91EE8-EBDF-451B-8A35-FFA5D546552D

Q34077400-58CB0EF6-76D5-4E2C-8282-582989049A46

Q34077400-6B56FBD7-66C0-4A22-971C-78591F606D9F

Q34077400-6E51ED28-2E0E-441F-AB17-B0A76D2C7392

Q34077400-73361A86-771C-4BB7-98AF-A16C380C6FC7

Q34077400-83FD39DB-336E-47DC-92BD-15440E51F8AA

P304

Q34077400-D9EDA10D-D9DE-4C93-8F88-4C3930A82467

P31

Q34077400-736813C8-0117-4698-9955-EAF476E32672

P356

Q34077400-EDC8BB88-B3E2-4402-B94D-16E57E880EF3

P407

Q34077400-43CE6A1D-016E-4A7A-9A69-8F81E1D276F9

P433

Q34077400-89F03EB8-6DE0-4D2E-B8EF-F3B2D5A8C3B4

P478

Q34077400-F2E2A3FF-E870-4D24-BCDD-3D0DA79954E8

P577

Q34077400-5543FD17-C5F1-4F66-9860-C3590E8006BD

P5875

Q34077400-3A36FE34-15F9-4D83-8DE5-4B435C50C950

P698

Q34077400-2DCDA1D7-315E-478A-9E11-E37B6CC0AC17

P921

Q34077400-42AC0745-3B14-4B35-8DB7-86EEAD485CD8

P932

Q34077400-8B14C8B5-4459-403E-8447-E732F091325F

P356

P1433

P1476

Recommendations for the definition of clinical responder in insulin preservation studies

@en

P2093

Craig A Beam

http://www.w3.org/2001/XMLSchema#string

Jerry P Palmer

http://www.w3.org/2001/XMLSchema#string

Stephen E Gitelman

http://www.w3.org/2001/XMLSchema#string

Type 1 Diabetes TrialNet Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.

AN INVESTIGATION OF THE EFFECT OF MISCLASSIFICATION ON THE PROPERTIES OF CHI-2-TESTS IN THE ANALYSIS OF CATEGORICAL DATA.

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.

P304

3120-3127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB14-0095

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261603636

http://www.w3.org/2001/XMLSchema#string

P698

24722251

http://www.w3.org/2001/XMLSchema#string

P921

P932

4141373

http://www.w3.org/2001/XMLSchema#string